Sharlene M Day

List of Publications by Citations

Source: https://exaly.com/author-pdf/2299823/sharlene-m-day-publications-by-citations.pdf

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2,205 24 46 g-index

84 3,081 10.1 4.75 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
68	Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. <i>Blood</i> , 2005 , 105, 192-8	2.2	244
67	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). <i>Circulation</i> , 2018 , 138, 1387-1398	16.7	210
66	Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. <i>Circulation</i> , 2010 , 121, 997-1004	16.7	173
65	Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. <i>Circulation</i> , 2003 , 107, 2601-6	16.7	137
64	Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1349-1357	27.4	107
63	Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. <i>Nature Medicine</i> , 2006 , 12, 181-9	50.5	94
62	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2020 , 142, e558-e631	16.7	77
61	Multidimensional structure-function relationships in human Etardiac myosin from population-scale genetic variation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 6701-6	11.5	68
60	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020 , 141, 828-842	16.7	66
59	Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e000067	5.2	59
58	Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 434-43		58
57	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. <i>Genome Medicine</i> , 2019 , 11, 5	14.4	54
56	Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2016 , 134, 1738-1748	16.7	50
55	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 1153-1	1602	45
54	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. <i>Circulation</i> , 2020 , 141, 1371-1383	16.7	43
53	Supercomputing for the parallelization of whole genome analysis. <i>Bioinformatics</i> , 2014 , 30, 1508-13	7.2	41
52	The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. <i>JAMA Cardiology</i> , 2017 , 2, 419-42	£ ^{6.2}	35

(2020-2016)

51	Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. Journal of Immunology, 2016 , 197, 2353-61	5.3	35
50	Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. <i>Circulation: Heart Failure</i> , 2013 , 6, 544-9	7.6	35
49	Tuning cardiac performance in ischemic heart disease and failure by modulating myofilament function. <i>Journal of Molecular Medicine</i> , 2007 , 85, 911-21	5.5	31
48	Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis. <i>Journal of Virology</i> , 2015 , 89, 468-79	6.6	28
47	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		27
46	Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 99, 197-206	5.8	25
45	MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 127, 165-173	5.8	24
44	17-Lestradiol ameliorates age-associated sarcopenia and improves late-life physical function in male mice but not in females or castrated males. <i>Aging Cell</i> , 2019 , 18, e12920	9.9	23
43	Cardiac risks associated with marathon running. Sports Health, 2010, 2, 301-6	4.7	23
42	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2020 , 5, 83-91	16.2	23
41	Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017 , 19, 107	6.9	22
40	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. <i>Heart Failure Clinics</i> , 2018 , 14, 119-128	3.3	22
39	Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup. <i>Genetics in Medicine</i> , 2018 , 20, 69-75	8.1	21
38	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018 , 11, e005191	7.6	21
37	Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. <i>Circulation</i> , 2018 , 137, 419-421	16.7	20
36	Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. <i>JCI Insight</i> , 2020 , 5,	9.9	20
35	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021 , 42, 1988-1996	9.5	20
34	Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, 396-405	5.2	19

33	Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. <i>Pflugers Archiv European Journal of Physiology</i> , 2019 , 471, 781-793	4.6	17
32	Women Representation Among Cardiology Journal Editorial Boards. <i>Circulation</i> , 2020 , 141, 603-605	16.7	16
31	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry. <i>Circulation: Heart Failure</i> , 2020 , 13, e007230	7.6	16
30	Differential protein expression and basal lamina remodeling in human heart failure. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 585-96	3.1	16
29	Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection. <i>Virology</i> , 2016 , 498, 57-68	3.6	15
28	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. <i>Open Heart</i> , 2017 , 4, e000615	3	15
27	Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy. <i>Clinics in Sports Medicine</i> , 2015 , 34, 489-505	2.6	14
26	Exercise in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2009 , 2, 407-	·1 54 3	12
25	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003062	5.2	10
24	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021 , 42, 3932-3944	9.5	6
23	Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology. <i>JCI Insight</i> , 2020 , 5,	9.9	5
22	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	5
21	Discordant clinical features of identical hypertrophic cardiomyopathy twins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
20	Whole-Exome Sequencing Reveals and Mutations as a Potential Digenic Cause of Left Ventricular Noncompaction. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e001966	5.2	4
19	Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death. <i>International Journal of Cardiology</i> , 2019 , 274, 226-	-231	4
18	Genetic engineering and therapy for inherited and acquired cardiomyopathies. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1080, 437-50	6.5	4
17	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2021 , 17, 303-31	3 ^{3.3}	4
16	Exercise Prescription for the Athlete with Cardiomyopathy. <i>Cardiology Clinics</i> , 2016 , 34, 591-601	2.5	4

LIST OF PUBLICATIONS

15	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. <i>Genetics in Medicine</i> , 2021 , 23, 69-79	8.1	4
14	Nonobstructive Hypertrophic Cardiomyopathy-The High-Hanging Fruit. <i>JAMA Cardiology</i> , 2019 , 4, 235-	23 6.2	3
13	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. <i>Genetics in Medicine</i> , 2021 , 23, 1281-1287	8.1	3
12	Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	3
11	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". <i>Circulation</i> , 2019 , 139, 1559-1560	16.7	2
10	Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2021 , 10, e019944	6	2
9	Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome. <i>JACC Basic To Translational Science</i> , 2017 , 2, 122-131	8.7	1
8	Exercise for Patients With Hypertrophic Cardiomyopathy-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 481-482	27.4	1
7	Sex-Related Differences in Genetic Cardiomyopathies <i>Journal of the American Heart Association</i> , 2022 , e024947	6	1
6	Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121009521	7.6	1
5	A Parallel Need for Cardiovascular Care for Female Carriers of Duchenne and Becker Muscular Dystrophy <i>Journal of Cardiac Failure</i> , 2022 ,	3.3	1
4	Translation of New and Emerging Therapies for Genetic Cardiomyopathies <i>JACC Basic To Translational Science</i> , 2022 , 7, 70-83	8.7	O
3	Response by Saberi and Day to Letter Regarding Article, "Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart". <i>Circulation</i> , 2018 , 138, 333-334	16.7	
2	Hypertrophic Cardiomopathy106-115		
1	Response to Suay-Corredera et al. <i>Genetics in Medicine</i> , 2021 , 23, 2011-2012	8.1	